What is William Blair’s Estimate for JANX FY2024 Earnings?

Janux Therapeutics, Inc. (NASDAQ:JANX) – Investment analysts at William Blair dropped their FY2024 earnings per share (EPS) estimates for Janux Therapeutics in a research note issued to investors on Wednesday, November 6th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of ($1.28) for the year, down from their prior estimate of ($0.94). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.29) per share. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics’s revenue was down 82.6% compared to the same quarter last year.

A number of other research analysts have also recently issued reports on JANX. Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. UBS Group initiated coverage on Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a report on Thursday, November 7th. Scotiabank lowered their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Finally, Stifel Nicolaus began coverage on Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective for the company. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Janux Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $66.44.

Janux Therapeutics Stock Down 1.6 %

Janux Therapeutics stock opened at $52.84 on Monday. The stock has a 50-day simple moving average of $49.16 and a 200 day simple moving average of $46.40. Janux Therapeutics has a 12-month low of $5.80 and a 12-month high of $65.60. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -45.88 and a beta of 3.52.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the sale, the chief executive officer now owns 282,054 shares in the company, valued at approximately $15,101,171.16. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the sale, the insider now owns 3,162,851 shares in the company, valued at approximately $132,839,742. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the sale, the chief executive officer now owns 282,054 shares in the company, valued at approximately $15,101,171.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 420,610 shares of company stock worth $19,288,666. Corporate insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC raised its stake in shares of Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock worth $73,961,000 after purchasing an additional 34,069 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Janux Therapeutics during the 1st quarter worth approximately $739,000. Virtu Financial LLC bought a new stake in shares of Janux Therapeutics during the 1st quarter worth approximately $609,000. Vanguard Group Inc. raised its stake in shares of Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after purchasing an additional 378,477 shares in the last quarter. Finally, Blue Owl Capital Holdings LP bought a new stake in shares of Janux Therapeutics during the 2nd quarter worth approximately $1,676,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.